Filed in archive
Corporate and Industrial News
, Genomics, Proteomics and Bioinformatics
, Patents and Intellectual Property Rights
by ruth on May 15, 2006
The methodology, invented by Phillip Zamore, Ph.D. professor of biochemistry & molecular pharmacology, and Gyorgy Hutvagner, Ph.D, both of UMMS, provides methods for inhibition of small RNA function, such as microRNA function in vitro and in vivo. Dr. Zamore and his colleagues developed an elegant system of using short pieces of oligonucleotides that bind to the target microRNAs and block their function, thereby modulating target gene expression. These oligonucleotides are referred to as the anti-RISC oligonucleotides. These patents describe methods that can be used not only for advancing RNAi basic research, but also for developing miRNA-based therapeutics.
This will definitely strengthen Sirna's lead in RNAi-based therapy development. Financial details of the agreement were not disclosed.
Another molecule in Sirna's pipeline, intravitreal injection of Sirna-027 for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), showed promising Phase I clinical trials. Patients are currently being recruited for Phase II clinical studies.
Tags:
RNAi
genomics
biotech
technology
therapeutics
sirna+therapeutics
microrna+technology
licenses+micror
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/21919
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Sirna Therapeutics Licenses microRNA Technology From UMMS:
|
Rating: 9.00 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
